David M Gardner
Overview
Explore the profile of David M Gardner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Soroka C, Gardner D, Hazelton L
Acad Psychiatry
. 2021 Mar;
45(3):329-333.
PMID: 33660236
Objective: Cannabis use by people receiving mental health services is increasingly common, yet many psychiatrists have limited knowledge about the pharmacology of cannabis or its clinical effects. Though clearly relevant...
12.
Murphy A, Jacobs L, Gardner D
Can Pharm J (Ott)
. 2021 Feb;
154(1):42-51.
PMID: 33598059
Background: The Bloom Program, which began as a demonstration project, is an ongoing community pharmacy-based mental illness and addictions program funded by the government of Nova Scotia. To be eligible...
13.
Murphy A, Peltekian S, Helwig M, Macdonald M, Martin-Misener R, Saini B, et al.
JBI Evid Synth
. 2020 Nov;
19(1):242-250.
PMID: 33165178
Objective: The objective of this scoping review is to identify, map, and characterize the evidence for assessments that measure driving performance in people taking benzodiazepine receptor agonists. Introduction: Benzodiazepines and...
14.
Murphy A, OReilly C, Ataya R, Doucette S, Burge F, Salvador-Carulla L, et al.
Psychiatr Serv
. 2019 Nov;
71(3):293-296.
PMID: 31744430
Objective: The study's objective was to examine Canadian and Australian community pharmacists' experiences with people at risk of suicide. Methods: A survey was developed and administered online. Countries were compared...
15.
Haslam L, Gardner D, Murphy A
Res Social Adm Pharm
. 2019 Jul;
16(4):522-528.
PMID: 31327736
Background: The Bloom Program, a community pharmacy-based mental health and addictions care program, was developed and implemented to optimize pharmacists' care of eligible patients. Characterizing pharmacists' activities in the Bloom...
16.
Shaw J, Murphy A, Turner J, Gardner D, Silvius J, Bouck Z, et al.
Healthc Policy
. 2019 Jul;
14(4):39-51.
PMID: 31322113
Policies have been put in place internationally to reduce the overuse of certain medications that have a high risk of harm, such as sedative-hypnotic drugs for insomnia or opioids for...
17.
Murphy A, Gardner D, Jacobs L
Can Pharm J (Ott)
. 2019 Jun;
152(3):186-192.
PMID: 31156732
Background: The Bloom Program was designed to enhance pharmacists' care of people with lived experience of mental illness and addictions in Nova Scotia. The Program's demonstration period was from September...
18.
Murphy A, OReilly C, Ataya R, Doucette S, Martin-Misener R, Rosen A, et al.
SAGE Open Med
. 2019 Feb;
7:2050312118820344.
PMID: 30728964
Background: There is limited information available regarding community pharmacists' stigma of suicide. Pharmacists regularly interact with people at risk of suicide and stigmatizing attitudes may impact care. Objective: To measure...
19.
Murphy A, Peltekian S, Gardner D
JMIR Ment Health
. 2018 Dec;
5(4):e12428.
PMID: 30545812
Background: Men with mental health and addictions problems seek information and help from health service providers and community support less often than women with such problems. Online health resources offer...
20.
El-Den S, OReilly C, Gardner D, Murphy A, Chen T
Women Health
. 2018 Nov;
59(6):615-630.
PMID: 30481138
Perinatal depression (PND) screening is encouraged in healthcare settings. We aimed to develop and content validate a basic PND knowledge questionnaire for use among pharmacists and potentially other primary healthcare...